Quantcast

International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier

January 11, 2010

JERUSALEM, Jan. 11 /PRNewswire-FirstCall/ — IDenta Corp. (PinkSheets: IDTA) announced today that the Identa Alert for TNT/PETN/RDX/NITRATE Explosive Identifier is actually a General Screening Explosive Identifier.

This kit has been used to identify TNT,PETN,RDX and Nitrates but with the 3 ampoules it contains, the following substances can be identified with this one kit which makes it a General Screening Explosive Identifier..

Ampoule 1: TNT, DNT, Tetryl.

Ampoule 1+2: PETN, RDX, HMX, EGDN, NG, Nitrocellulose.

Ampoule 1+2+3: Inorganic nitrate – Ammonium nitrate, Potassium nitrate and Urea nitrate.

By using this one kit, most substances suspected as known explosives can be identified.

For substances suspected as TATP and Chlorate, Identa has separate kits .

This kit is a very efficient, easy to use, reliable and inexpensive tool to be used by the many military, homeland security and other agencies around the world.

Identa Corp. CEO Yaacov Shoham commented, ” With this one simple kit we are able to test for up to nine kinds of substances suspected as explosives plus the three inorganic nitrates. This identifying kit as far as we know is unique for our company. We expect demand to be great for this kit due to the fact it is possible to identify so many suspected substances in one simple kit.”

Information concerning IDenta’s entire product line may be found at www.IDenta.biz

ABOUT IDENTA

Since 2003, IDenta Corporation has been recognized as a worldwide leader in the development of proprietary on-site drug, drug precursor and explosive detection kits. IDenta develops, manufactures and distributes products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

DISCLAIMER

Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements” that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management’s expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

For Investor Relations, lobbying interests or information concerning IDenta’s products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com, www.identa.biz.

For information about the Accutest® – IDenta products in the US, please contact: Mr. Eyal Golan, COO, JANT PHARMACAL CORPORATION, 16255 Ventura Blvd. #505, Encino, CA 91436, Toll Free: 800-676-5565, 661-478-0582 (mobile), golan@accutest.net, www.accutestidenta.net.

SOURCE IDenta Corp.


Source: newswire



comments powered by Disqus